Literature DB >> 30201452

Baicalein represses TGF-β1-induced fibroblast differentiation through the inhibition of miR-21.

Xinjian Cui1, Xionghua Sun1, Fanqing Lu1, Xiaogang Jiang2.   

Abstract

Fibroblast-to-myofibroblast differentiation is a highly important pathological characteristic of pulmonary fibrosis. In this study, we aimed to investigate the effects and mechanisms of baicalein on the differentiation of human lung fibroblasts. Baicalein reduced the levels of α-smooth muscle actin (α-SMA) mRNA and protein expression in TGF-β1-treated human lung fibroblasts. It also decreased the contents of collagen type I and fibronectin in time- and dose-dependent manners, and retarded TGF-β1-stimulated α-SMA filament formation. Baicalein diminished the expression of miR-21, and miR-21 mimics partially antagonized the effects of baicalein. Additionally, Baicalein inhibited the miR-21 transcriptor STAT3 activity but not AP-1 activity. Moreover, the expression of Spry 1 protein, a miR-21 known target, was improved by baicalein treatment, but the level of Smurf2 protein, another miR-21 target, was not interfered. Collectively, these results demonstrated that baicalein can attenuate TGF-β1-induced human lung fibroblast differentiation by inhibiting the miR-21 expression.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Baicalein; Fibroblast-To-Myofibroblast Differentiation; Human Lung Fibroblast; microRNA-21; α-SMA Filament

Mesh:

Substances:

Year:  2018        PMID: 30201452     DOI: 10.1016/j.taap.2018.09.007

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  2 in total

Review 1.  A systematic review of outcomes in COVID-19 patients treated with western medicine in combination with traditional Chinese medicine versus western medicine alone.

Authors:  Ruizhe Yu; Shihan Zhang; Dejian Zhao; Zhanpeng Yuan
Journal:  Expert Rev Mol Med       Date:  2022-01-06       Impact factor: 5.600

2.  Baicalein inhibits macrophage lipid accumulation and inflammatory response by activating the PPARγ/LXRα pathway.

Authors:  Zi-Zhen Zhang; Xiao-Hua Yu; Wei-Hua Tan
Journal:  Clin Exp Immunol       Date:  2022-09-29       Impact factor: 5.732

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.